{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:06:23Z","timestamp":1792037183478,"version":"4.4.0"},"reference-count":353,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bbcan.2026.189557","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:17:43Z","timestamp":1771028263000},"page":"189557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Glioblastoma cell plasticity: A new paradigm in glioblastoma therapeutic resistance"],"prefix":"10.1016","volume":"1881","author":[{"given":"Teng","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiling","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2026.189557_bb0005","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.bbcan.2026.189557_bb0010","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017\u20132021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0015","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.ccell.2024.08.012","article-title":"Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence","volume":"42","author":"Watson","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189557_bb0020","first-page":"C1045","article-title":"Hunting glioblastoma recurrence: glioma stem cells as retrospective targets","volume":"328","author":"Emir","year":"2025","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.bbcan.2026.189557_bb0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189557_bb0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/neuonc\/noae164","article-title":"Contemporary prognostic signatures and refined risk stratification of gliomas: an analysis of 4400 tumors","volume":"27","author":"Ghosh","year":"2025","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0035","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0040","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.22.01000","article-title":"Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma","volume":"41","author":"Bouffet","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0045","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009175","article-title":"Co-evolution of glioma and immune microenvironment","volume":"12","author":"Elguindy","year":"2024","journal-title":"J. Immunother Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb0055","first-page":"319","article-title":"Evolution-driven crosstalk between glioblastoma and the tumor microenvironment","volume":"20","author":"Wu","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0060","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/neuonc\/noab269","article-title":"Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma","volume":"24","author":"Yabo","year":"2021","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0065","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41588-025-02168-4","article-title":"Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics","volume":"57","author":"Spitzer","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2026.189557_bb0070","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noad179.0490","article-title":"EPCO-27. Reconstruction of the spatial ecosystem of glioblastoma reveals recurrent relationships between tumor cell states and tumor microenvironment","volume":"25","author":"Adabbo","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0075","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s41588-025-02167-5","article-title":"The multilayered transcriptional architecture of glioblastoma ecosystems","volume":"57","author":"Nomura","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2026.189557_bb0080","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189557_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/freae.2025.1519449","article-title":"Epigenetic mechanisms of plasticity and resistance in glioblastoma: therapeutic targets and implications","volume":"3","author":"Amirmahani","year":"2025","journal-title":"Front. Epigenet. Epigenom."},{"key":"10.1016\/j.bbcan.2026.189557_bb0090","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3390\/cancers12061622","article-title":"Cellular plasticity and tumor microenvironment in gliomas: the struggle to hit a moving target","volume":"12","author":"Gargini","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189557_bb0095","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/biology11020313","article-title":"Adapt to persist: glioblastoma microenvironment and epigenetic regulation on cell plasticity","volume":"11","author":"Uribe","year":"2022","journal-title":"Biol.-Basel"},{"key":"10.1016\/j.bbcan.2026.189557_bb0100","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189557_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2022.09.005","article-title":"Challenges in glioblastoma research: focus on the tumor microenvironment","volume":"9","author":"Bikfalvi","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb0110","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.7150\/thno.69605","article-title":"TGFBI secreted by tumor-associated macrophages promotes glioblastoma stem cell-driven tumor growth via integrin \u03b1v\u03b25-Src-Stat3 signaling","volume":"12","author":"Peng","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bbcan.2026.189557_bb0115","article-title":"Unifying models of glioblastoma\u2019s intratumoral heterogeneity","volume":"2","author":"Lam","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"key":"10.1016\/j.bbcan.2026.189557_bb0120","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s43587-025-00840-2","article-title":"Transcriptional profiles of mouse oligodendrocyte precursor cells across the lifespan","volume":"5","author":"Heo","year":"2025","journal-title":"Nat. Aging"},{"key":"10.1016\/j.bbcan.2026.189557_bb0125","article-title":"PRRC2B modulates oligodendrocyte progenitor cell development and myelination by stabilizing Sox2 mRNA","volume":"43","author":"Zhang","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2026.189557_bb0130","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/s41467-022-29068-z","article-title":"The oligodendrocyte transcription factor 2 OLIG2 regulates transcriptional repression during myelinogenesis in rodents","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb0135","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/dneu.22849","article-title":"Using the lineage determinants Olig2 and Sox10 to explore transcriptional regulation of oligodendrocyte development","volume":"81","author":"Sock","year":"2021","journal-title":"Dev. Neurobiol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112235","article-title":"Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma","volume":"42","author":"Walentynowicz","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2026.189557_bb0145","doi-asserted-by":"crossref","first-page":"1452172","DOI":"10.3389\/fimmu.2024.1452172","article-title":"Single-cell and spatial transcriptome assays reveal heterogeneity in gliomas through stress responses and pathway alterations","volume":"15","author":"He","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0150","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf201.1721","article-title":"TMET-30. Uncovering the metabolic programs underlying malignant cell state heterogeneity in glioblastoma","volume":"27","author":"Jucht","year":"2025","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0155","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40478-024-01769-0","article-title":"Spatial transcriptomics reveals segregation of tumor cell states in glioblastoma and marked immunosuppression within the perinecrotic niche","volume":"12","author":"Liu","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb0160","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1186\/s12967-025-06706-w","article-title":"Single-cell and spatial transcriptome analyses reveal MAZ(+) NPC-like clusters as key role contributing to glioma recurrence and drug resistance","volume":"23","author":"Gu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54750-9","article-title":"Transcription factors ASCL1 and OLIG2 drive glioblastoma initiation and co-regulate tumor cell types and migration","volume":"15","author":"Myers","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb0170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41698-025-00830-y","article-title":"An integrated perspective on single-cell and spatial transcriptomic signatures in high-grade gliomas","volume":"9","author":"Lemoine","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0175","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13059-025-03670-y","article-title":"A new IDH-independent hypermethylation phenotype is associated with astrocyte-like cell state in glioblastoma","volume":"26","author":"Costa","year":"2025","journal-title":"Genome Biol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0180","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20209522","article-title":"Neural G0: a quiescent-like state found in neuroepithelial-derived cells and glioma","volume":"17","author":"O\u2019Connor","year":"2021","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0185","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41586-023-06678-1","article-title":"Glioma synapses recruit mechanisms of adaptive plasticity","volume":"623","author":"Taylor","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189557_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217884","article-title":"Mechanisms and therapeutic implications of glioma-neuron interactions","volume":"629","author":"Wang","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189557_bb0195","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-neuro-111020-092702","article-title":"Neural signaling in cancer","volume":"45","author":"Keough","year":"2022","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.bbcan.2026.189557_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202506813","article-title":"Cancer neuroscience: decoding neural circuitry in tumor evolution for targeted therapy","volume":"12","author":"Yuan","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bbcan.2026.189557_bb0205","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12264-024-01258-3","article-title":"From physiology to pathology of astrocytes: highlighting their potential as therapeutic targets for CNS injury","volume":"41","author":"Yuan","year":"2025","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.bbcan.2026.189557_bb0210","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1535-7163.MCT-21-0903","article-title":"Transcription factor\u2013forced astrocytic differentiation impairs human glioblastoma growth in vitro and in vivo","volume":"22","author":"Trovato","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189557_bb0215","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s13046-023-02811-0","article-title":"Different states of stemness of glioblastoma stem cells sustain glioblastoma subtypes indicating novel clinical biomarkers and high-efficacy customized therapies","volume":"42","author":"Visioli","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb0220","article-title":"Characterization of tumor-associated reactive astrocytes in gliomas by single-cell and bulk tumor sequencing","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002893","article-title":"Identification and characterization of tumor-associated astrocyte subpopulations and their interactions with the tumor microenvironment in experimental glioblastomas","volume":"23","author":"Ghosh","year":"2025","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2025.1685491","article-title":"Aquaporin-4 in glioblastoma: a nexus of glymphatic dysfunction, edema, immune evasion, and treatment resistance","volume":"19","author":"Casta\u00f1eyra-Ruiz","year":"2025","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.bbcan.2026.189557_bb0235","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1186\/s12885-025-15291-6","article-title":"Single-cell and spatial transcriptomics reveal lactylation-associated tumor cell clusters and define a prognostic risk model in glioblastoma","volume":"25","author":"Han","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb0240","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176851","article-title":"Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation","volume":"134","author":"Wang","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189557_bb0245","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.stemcr.2020.01.007","article-title":"Adult human glioblastomas harbor radial glia-like cells","volume":"14","author":"Wang","year":"2020","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.bbcan.2026.189557_bb0250","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13073-022-01109-8","article-title":"Elucidating the diversity of malignant mesenchymal states in glioblastoma by integrative analysis","volume":"14","author":"Chanoch-Myers","year":"2022","journal-title":"Genome Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0255","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature08712","article-title":"The transcriptional network for mesenchymal transformation of brain tumours","volume":"463","author":"Carro","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189557_bb0260","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s40478-025-02036-6","article-title":"Single-cell transcriptome sequencing reveals new epithelial-stromal associated mesenchymal-like subsets in recurrent gliomas","volume":"13","author":"Li","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb0265","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ccell.2021.05.002","article-title":"Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma","volume":"39","author":"Hara","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189557_bb0270","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.64846","article-title":"NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1","volume":"10","author":"Marques","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.bbcan.2026.189557_bb0275","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13578-024-01332-3","article-title":"Single-cell multi-omics analysis reveals candidate therapeutic drugs and key transcription factor specifically for the mesenchymal subtype of glioblastoma","volume":"14","author":"Yang","year":"2024","journal-title":"Cell Biosci."},{"key":"10.1016\/j.bbcan.2026.189557_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087047","article-title":"Glioblastoma microenvironment and invasiveness: new insights and therapeutic targets","volume":"24","author":"Erices","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189557_bb0285","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives","volume":"17","author":"Lin","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0290","doi-asserted-by":"crossref","DOI":"10.15252\/msb.202010105","article-title":"Modeling glioblastoma heterogeneity as a dynamic network of cell states","volume":"17","author":"Larsson","year":"2021","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0295","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/2159-8290.CD-23-1336","article-title":"Glioblastoma cortical organoids recapitulate cell-state heterogeneity and intercellular transfer","volume":"15","author":"Mangena","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189557_bb0300","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1038\/s41467-025-61999-1","article-title":"The invasion phenotypes of glioblastoma depend on plastic and reprogrammable cell states","volume":"16","author":"Doroszko","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb0305","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/neuonc\/noae011","article-title":"Cancer stem cell hypothesis 2.0 in glioblastoma: where are we now and where are we going?","volume":"26","author":"Sloan","year":"2024","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0310","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s40478-022-01459-9","article-title":"Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation","volume":"10","author":"Lakis","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb0315","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41419-025-07617-w","article-title":"Temozolomide promotes glioblastoma stemness expression through senescence-associated reprogramming via HIF1\u03b1\/HIF2\u03b1 regulation","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb0320","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41419-020-03380-2","article-title":"Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-myc","volume":"12","author":"Lee","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb0325","article-title":"Machine learning and multi-omics analysis reveal key regulators of proneural\u2013mesenchymal transition in glioblastoma","volume":"15","author":"Xu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189557_bb0330","doi-asserted-by":"crossref","first-page":"8811","DOI":"10.2147\/IJN.S515771","article-title":"Glioma-associated mesenchymal stromal\/stem cells derived exosomal miR-191 promotes the proneural-to-mesenchymal transition in glioblastoma cells via PTEN\/PI3K\/AKT signaling","volume":"20","author":"Lv","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbcan.2026.189557_bb0335","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1186\/s12967-025-07034-9","article-title":"Phenotypic variations in glioma stem cells: regulatory mechanisms and implications for therapeutic strategies","volume":"23","author":"Tian","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0340","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3390\/cells13181574","article-title":"Metabolic reprogramming in glioblastoma multiforme: a review of pathways and therapeutic targets","volume":"13","author":"Cortes Ballen","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189557_bb0345","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1186\/s12967-023-04624-3","article-title":"METTL3-mediated HOTAIRM1 promotes vasculogenic mimicry icontributionsn glioma via regulating IGFBP2 expression","volume":"21","author":"Wu","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0350","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41576-023-00601-0","article-title":"The epithelial\u2013mesenchymal plasticity landscape: principles of design and mechanisms of regulation","volume":"24","author":"Haerinck","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bbcan.2026.189557_bb0355","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.biomaterials.2016.02.014","article-title":"Low doses of PEG-coated gold nanoparticles sensitize solid tumors to cold plasma by blocking the PI3K\/AKT-driven signaling axis to suppress cellular transformation by inhibiting growth and EMT","volume":"87","author":"Kaushik","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbcan.2026.189557_bb0360","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1158\/0008-5472.CAN-17-1294","article-title":"S100A4 is a biomarker and regulator of glioma stem cells that is critical for mesenchymal transition in glioblastoma","volume":"77","author":"Chow","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb0365","first-page":"4277","article-title":"Snail expression contributes to temozolomide resistance in glioblastoma","volume":"11","author":"Liang","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb0370","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3724\/abbs.2024061","article-title":"Deciphering the role of transcription factors in glioblastoma cancer stem cells","volume":"56","author":"Li","year":"2024","journal-title":"ABBS"},{"key":"10.1016\/j.bbcan.2026.189557_bb0375","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1080\/15384101.2021.1933303","article-title":"miR-451 suppresses EMT and metastasis in glioma cells","volume":"20","author":"Nan","year":"2021","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2026.189557_bb0380","first-page":"1105","article-title":"MicroRNA miR-451 downregulates the PI3K\/AKT pathway through CAB39 in human glioma","volume":"40","author":"Tian","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0385","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.7150\/ijbs.102051","article-title":"SUMOylation modification of HNRNPK at the K422 site promotes invasion in glioblastoma","volume":"20","author":"Zhao","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbcan.2026.189557_bb0390","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12935-025-03823-w","article-title":"HIF-1\u03b1 and HIF-2\u03b1: synergistic regulation of glioblastoma malignant progression during hypoxia and apparent chemosensitization in response to hyperbaric oxygen","volume":"25","author":"Wang","year":"2025","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbcan.2026.189557_bb0395","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.7150\/thno.95766","article-title":"Hypoxia-driven M2-polarized macrophages facilitate the epithelial-mesenchymal transition of glioblastoma via extracellular vesicles","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.bbcan.2026.189557_bb0400","article-title":"Tumor-associated monocytes promote mesenchymal transformation through EGFR signaling in glioma","volume":"4","author":"Chen","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0405","article-title":"Extracellular vesicles induce mesenchymal transition and therapeutic resistance in glioblastomas through NF-\u03baB\/STAT3 signaling","volume":"4","author":"Schweiger","year":"2020","journal-title":"Adv. Biosyst."},{"key":"10.1016\/j.bbcan.2026.189557_bb0410","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1586\/14737175.2014.964211","article-title":"NF-\u03baB and STAT3 in glioblastoma: therapeutic targets coming of age","volume":"14","author":"Gray","year":"2014","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.bbcan.2026.189557_bb0415","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008967","article-title":"ScRNA-seq reveals novel immune-suppressive T cells and investigates CMV-TCR-T cells cytotoxicity against GBM","volume":"12","author":"Long","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb0420","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.cell.2024.03.029","article-title":"Integrative spatial analysis reveals a multi-layered organization of glioblastoma","volume":"187","author":"Greenwald","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189557_bb0425","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10456-023-09876-7","article-title":"Pathological angiogenesis: mechanisms and therapeutic strategies","volume":"26","author":"Dudley","year":"2023","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bbcan.2026.189557_bb0430","doi-asserted-by":"crossref","first-page":"19634","DOI":"10.18632\/oncotarget.3839","article-title":"CD44 enhances tumor aggressiveness by promoting tumor cell plasticity","volume":"6","author":"Paulis","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189557_bb0435","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1038\/s41418-018-0149-9","article-title":"BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma","volume":"25","author":"Porc\u00f9","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2026.189557_bb0440","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/neuonc\/not029","article-title":"CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia","volume":"15","author":"Mao","year":"2013","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0445","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nature09624","article-title":"Glioblastoma stem-like cells give rise to tumour endothelium","volume":"468","author":"Wang","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189557_bb0450","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1158\/1078-0432.CCR-12-1281","article-title":"Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance","volume":"19","author":"Jahangiri","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb0455","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41419-024-06678-7","article-title":"ID1high\/activin Ahigh glioblastoma cells contribute to resistance to anti-angiogenesis therapy through malformed vasculature","volume":"15","author":"Choi","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb0460","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1101\/gad.14.1.34","article-title":"Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha","volume":"14","author":"Ravi","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2026.189557_bb0465","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13046-020-01709-5","article-title":"The role of microenvironment in tumor angiogenesis","volume":"39","author":"Jiang","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb0470","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40364-015-0034-3","article-title":"Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets","volume":"3","author":"Mao","year":"2015","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb0475","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.biopha.2016.03.010","article-title":"The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment","volume":"80","author":"Li","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189557_bb0480","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41419-019-2102-3","article-title":"Tenascin-cmediated vasculogenic mimicry formation via regulation of MMP2\/MMP9 in glioma","volume":"10","author":"Cai","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb0485","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/s41388-018-0525-4","article-title":"IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma","volume":"38","author":"Liu","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189557_bb0490","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70014","article-title":"Single-cell transcriptomic analysis of glioblastoma reveals pericytes contributing to the blood-brain-tumor barrier and tumor progression","volume":"5","author":"Li","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.bbcan.2026.189557_bb0495","first-page":"3892","article-title":"Prrx1 promotes resistance to temozolomide by upregulating ABCC1 and inducing vasculogenic mimicry in glioma","volume":"12","author":"Chen","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb0500","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3892\/or.2014.3454","article-title":"Mammalian target of rapamycin signaling is involved in the vasculogenic mimicry of glioma via hypoxia-inducible factor-1\u03b1","volume":"32","author":"Huang","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2026.189557_bb0505","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1007\/s00018-019-03199-x","article-title":"Stem cells in tissues, organoids, and cancers","volume":"76","author":"Wang","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbcan.2026.189557_bb0510","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noag003","article-title":"Tumor microenvironment shapes the spatial organization of glioblastoma cell states","author":"Prakash","year":"2026","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0515","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.stem.2019.11.015","article-title":"Outer radial glia-like cancer stem cells contribute to heterogeneity of glioblastoma","volume":"26","author":"Bhaduri","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbcan.2026.189557_bb0520","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/neuonc\/noac157","article-title":"Oct4A palmitoylation modulates tumorigenicity and stemness in human glioblastoma cells","volume":"25","author":"Chen","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0525","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1038\/s41467-023-39845-z","article-title":"Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb0530","doi-asserted-by":"crossref","first-page":"9137","DOI":"10.3390\/ijms24119137","article-title":"Glioblastoma metabolism: insights and therapeutic strategies","volume":"24","author":"Bernhard","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189557_bb0535","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/neuonc\/noae161","article-title":"Mapping tumor habitats in isocitrate dehydrogenase -wild type glioblastoma: integrating MRI, pathologic, and RNA data from the Ivy glioblastoma atlas project","volume":"27","author":"Park","year":"2024","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.bbcan.2026.189557_bb0540","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10555-023-10100-7","article-title":"Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies","volume":"42","author":"Higginbottom","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbcan.2026.189557_bb0545","article-title":"Polo-like kinase 4 accelerates glioma malignant progression and vasculogenic mimicry by phosphorylating EphA2","volume":"611","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189557_bb0550","doi-asserted-by":"crossref","first-page":"83976","DOI":"10.18632\/oncotarget.6930","article-title":"Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation","volume":"7","author":"Rong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189557_bb0555","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.202200122","article-title":"Neuron-glial interactions in health and brain cancer","volume":"6","author":"Pan","year":"2022","journal-title":"Adv. Biol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189518","article-title":"Astrocytes in glioblastoma tumor microenvironment","volume":"1881","author":"Cui","year":"2026","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb0565","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40478-020-00916-7","article-title":"Annexin A2-STAT3-oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma","volume":"8","author":"Matsumoto","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb0570","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf145","article-title":"Glioportal: a comprehensive transcriptomic resource unveiling ligand-mediated mesenchymal transition in glioblastoma","author":"Pang","year":"2025","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0575","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/genes14030651","article-title":"EGFRvIII promotes the proneural\u2013mesenchymal transition of glioblastoma multiforme and reduces its sensitivity to temozolomide by regulating the NF-\u03baB\/ALDH1A3 axis","volume":"14","author":"Shi","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.bbcan.2026.189557_bb0580","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14709","article-title":"Nuclear autoantigenic sperm protein facilitates glioblastoma progression and radioresistance by regulating the ANXA2\/STAT3 axis","volume":"30","author":"Qiu","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.bbcan.2026.189557_bb0585","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.ymthe.2021.10.028","article-title":"FOSL1 promotes proneural-to-mesenchymal transition of glioblastoma stem cells via UBC9\/CYLD\/NF-\u03baB axis","volume":"30","author":"Chen","year":"2022","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.bbcan.2026.189557_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218216","article-title":"Tumor microenvironment in glioblastoma: the central role of the hypoxic\u2013necrotic core","volume":"639","author":"Bayona","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189557_bb0595","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40364-025-00788-w","article-title":"Epigenetic regulation of histone modifications in glioblastoma: recent advances and therapeutic insights","volume":"13","author":"Zhang","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb0600","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf169","article-title":"BRD2 bromodomain-mediated regulation of cell state plasticity modulates therapy response in glioblastoma","author":"Vadla","year":"2025","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0605","article-title":"Epigenetic underpinnings of inflammation: a key to unlock the tumor microenvironment in glioblastoma","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0610","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179853","article-title":"Spatial analysis of recurrent glioblastoma reveals perivascular niche organization","volume":"9","author":"Onubogu","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbcan.2026.189557_bb0615","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/s12885-024-12221-w","article-title":"Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients","volume":"24","author":"Dvorakova","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb0620","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/emmm.201302827","article-title":"The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance","volume":"5","author":"Siebzehnrubl","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0625","doi-asserted-by":"crossref","first-page":"vi22","DOI":"10.1093\/neuonc\/noab196.082","article-title":"STEM-07. PRC2 maintains a cancer stem cell phenotype in glioblastoma multiforme via chromatin modification of H3K27me3","volume":"23","author":"Korleski","year":"2021","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0630","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.semcancer.2020.12.022","article-title":"Targeting epigenetic regulatory machinery to overcome cancer therapy resistance","volume":"83","author":"Guo","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0635","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1038\/onc.2009.252","article-title":"Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha","volume":"28","author":"Soeda","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189557_bb0640","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/biomedicines5020029","article-title":"NF-\u03baB signalling in glioblastoma","volume":"5","author":"Soubannier","year":"2017","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbcan.2026.189557_bb0645","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.gendis.2015.02.001","article-title":"Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs","volume":"2","author":"Safa","year":"2015","journal-title":"Genes Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb0650","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-021-00857-0","article-title":"Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications","volume":"7","author":"Lopez-Bertoni","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189557_bb0655","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3233\/CBM-181460","article-title":"The clinicopathological significance of CD133 and Sox2 in astrocytic glioma","volume":"23","author":"Abdelrahman","year":"2018","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.bbcan.2026.189557_bb0660","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jmcb\/mjy080","article-title":"SOX2 in cancer stemness: tumor malignancy and therapeutic potentials","volume":"12","author":"Mamun","year":"2020","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0665","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41419-021-03733-5","article-title":"SOX2 promotes chemoresistance, cancer stem cells properties, and epithelial-mesenchymal transition by \u03b2-catenin and Beclin1\/autophagy signaling in colorectal cancer","volume":"12","author":"Zhu","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb0670","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910620","article-title":"The embryonic key pluripotent factor NANOG mediates glioblastoma cell migration via the SDF1\/CXCR4 pathway","volume":"22","author":"S\u00e1nchez-S\u00e1nchez","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189557_bb0675","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-020-00430-1","article-title":"Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents","volume":"6","author":"Zhou","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189557_bb0680","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41420-019-0155-9","article-title":"Sustained NF-\u03baB-STAT3 signaling promotes resistance to Smac mimetics in Glioma stem-like cells but creates a vulnerability to EZH2 inhibition","volume":"5","author":"da Hora","year":"2019","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bbcan.2026.189557_bb0685","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.cmet.2022.08.002","article-title":"Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of I\u03baB\u03b1","volume":"34","author":"Guo","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbcan.2026.189557_bb0690","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41419-020-2520-2","article-title":"NF-kappa B interacting long noncoding RNA enhances the Warburg effect and angiogenesis and is associated with decreased survival of patients with gliomas","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb0695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/jca.54402","article-title":"HIF1\u03b1\/HIF2\u03b1 induces glioma cell dedifferentiation into cancer stem cells through Sox2 under hypoxic conditions","volume":"13","author":"Wang","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb0700","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1631\/jzus.B2200269","article-title":"Hypoxia-induced ROS aggravate tumor progression through HIF-1\u03b1-SERPINE1 signaling in glioblastoma","volume":"24","author":"Zhang","year":"2023","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.bbcan.2026.189557_bb0705","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00018-022-04529-2","article-title":"Atypical induction of HIF-1\u03b1 expression by pericellular Notch1 signaling suffices for the malignancy of glioblastoma multiforme cells","volume":"79","author":"Lee","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbcan.2026.189557_bb0710","article-title":"HIF-1\u03b1 inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression","volume":"10","author":"J K, A H, H W, S R, M K, M B","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb0715","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.immuni.2023.06.017","article-title":"Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression","volume":"56","author":"Sattiraju","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2026.189557_bb0720","article-title":"Hypoxia-driven protease legumain promotes immunosuppression in glioblastoma","volume":"4","author":"Pang","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0725","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.7150\/thno.35882","article-title":"HIF-1\u03b1\/Wnt signaling-dependent control of gene transcription regulates neuronal differentiation of glioblastoma stem cells","volume":"9","author":"Boso","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.bbcan.2026.189557_bb0730","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41419-022-05304-8","article-title":"HIF-\u03b1 activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis","volume":"13","author":"Su","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb0735","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.153","article-title":"BMP2 sensitizes glioblastoma stem-like cells to temozolomide by affecting HIF-1\u03b1 stability and MGMT expression","volume":"3","author":"Persano","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb0740","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2174\/0118715273277458231213063147","article-title":"Non-coding RNAs as key regulators of the Notch signaling pathway in glioblastoma: diagnostic, prognostic, and therapeutic targets","volume":"23","author":"Shahcheraghi","year":"2024","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.bbcan.2026.189557_bb0745","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0750","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s11060-011-0787-y","article-title":"MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors","volume":"107","author":"Mellai","year":"2012","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0755","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13148-018-0450-y","article-title":"Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma","volume":"10","author":"Hervouet","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bbcan.2026.189557_bb0760","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11060-010-0520-2","article-title":"Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas","volume":"104","author":"Rajendran","year":"2011","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0765","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1868-7083-5-9","article-title":"Specific inhibition of one DNMT1-including complex influences tumor initiation and progression","volume":"5","author":"Cheray","year":"2013","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bbcan.2026.189557_bb0770","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13148-025-01943-8","article-title":"Selective disruption of DNMT1\/ELK1 interactions induces DGKI re-expression and promotes temozolomide sensitivity of MGMTmethylated\/DGKImethylated glioblastoma","volume":"17","author":"Besson","year":"2025","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bbcan.2026.189557_bb0775","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1038\/onc.2014.334","article-title":"DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2","volume":"34","author":"Lopez-Bertoni","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189557_bb0780","first-page":"145","article-title":"Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas","volume":"6","author":"Wu","year":"2025","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2026.189557_bb0785","doi-asserted-by":"crossref","first-page":"25922","DOI":"10.18632\/oncotarget.25406","article-title":"Epigenetic dysregulation of TET2 in human glioblastoma","volume":"9","author":"Garc\u00eda","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189557_bb0790","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.32520","article-title":"Epigenetic downregulation of TET3 reduces genome-wide 5hmC levels and promotes glioblastoma tumorigenesis","volume":"146","author":"Carella","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb0795","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1016\/j.cell.2023.06.022","article-title":"Modeling epigenetic lesions that cause gliomas","volume":"186","author":"Rahme","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189557_bb0800","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.tranon.2019.09.006","article-title":"Inhibition of casein kinase II by CX-4945, but not yes-associated protein (YAP) by verteporfin, enhances the antitumor efficacy of temozolomide in glioblastoma","volume":"13","author":"Liu","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0805","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","article-title":"Mechanisms of action and resistance in histone methylation-targeted therapy","volume":"627","author":"Yamagishi","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189557_bb0810","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.509","article-title":"Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance","volume":"5","author":"Dahan","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb0815","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1038\/s41467-022-33943-0","article-title":"P300 promotes tumor recurrence by regulating radiation-induced conversion of glioma stem cells to vascular-like cells","volume":"13","author":"Muthukrishnan","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb0820","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/neuonc\/noaa103","article-title":"Increased activation of HDAC1\/2\/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma","volume":"22","author":"Yang","year":"2020","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0825","first-page":"3701","article-title":"Effects of SIRT1 silencing on viability, invasion and metastasis of human glioma cell lines","volume":"17","author":"Li","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbcan.2026.189557_bb0830","doi-asserted-by":"crossref","DOI":"10.2991\/978-94-6463-728-1","article-title":"Targeting mesenchymal monocyte-derived macrophages to enhance the sensitivity of glioblastoma to temozolomide by inhibiting TNF\/CELSR2\/p65\/Kla-HDAC1\/EPAS1 axis","author":"Gao","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb0835","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1038\/s41467-018-06968-7","article-title":"PRMT2 links histone H3R8 asymmetric dimethylation to oncogenic activation and tumorigenesis of glioblastoma","volume":"9","author":"Dong","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb0840","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/neuonc\/noaa128","article-title":"Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevents glioblastoma recurrence","volume":"22","author":"Kaur","year":"2020","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0845","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/0008-5472.CAN-13-0109","article-title":"Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma","volume":"73","author":"Natsume","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb0850","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/nm.4415","article-title":"Targeting glioma stem cells through combined BMI1 and EZH2 inhibition","volume":"23","author":"Jin","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0855","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/neuonc\/noad018","article-title":"Lysine-specific histone demethylase 1A (KDM1A\/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma","volume":"25","author":"Alejo","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0860","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/cancers11060878","article-title":"Targeting of histone demethylases KDM5A and KDM6B inhibits the proliferation of temozolomide-resistant glioblastoma cells","volume":"11","author":"Romani","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189557_bb0865","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/ijc.32649","article-title":"Glioblastoma initiating cells are sensitive to histone demethylase inhibition due to epigenetic deregulation","volume":"146","author":"Mallm","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb0870","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.181","article-title":"BRD4 regulates self-renewal ability and tumorigenicity of glioma-initiating cells by enrichment in the Notch1 promoter region","volume":"10","author":"Tao","year":"2020","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0875","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/ijc.30256","article-title":"OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models","volume":"139","author":"Berenguer-Daiz\u00e9","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb0880","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-022-05497-y","article-title":"BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression","volume":"13","author":"Tancredi","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb0885","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.molcel.2005.12.002","article-title":"Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing","volume":"20","author":"Cao","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbcan.2026.189557_bb0890","article-title":"Histone H3K9 lactylation confers temozolomide resistance in glioblastoma via LUC7L2-mediated MLH1 intron retention","volume":"11","author":"Yue","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbcan.2026.189557_bb0895","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/aps.2017.173","article-title":"MicroRNAs as biomarkers for human glioblastoma: progress and potential","volume":"39","author":"Huang","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbcan.2026.189557_bb0900","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nrc3166","article-title":"Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy","volume":"11","author":"Kasinski","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb0905","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1158\/0008-5472.CAN-07-3141","article-title":"Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation","volume":"68","author":"Coletta","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb0910","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.1073\/pnas.0401139101","article-title":"The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1","volume":"101","author":"Coletta","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189557_bb0915","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/ijc.28755","article-title":"Six1: a critical transcription factor in tumorigenesis","volume":"136","author":"Wu","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb0920","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1111\/jcmm.15192","article-title":"MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1","volume":"24","author":"Chen","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0925","article-title":"miR-1258 attenuates tumorigenesis through targeting E2F1 to inhibit PCNA and MMP2 transcription in glioblastoma","volume":"11","author":"Qin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0930","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1124\/pr.58.2.3","article-title":"Multidrug resistance-associated proteins: expression and function in the central nervous system","volume":"58","author":"Dallas","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbcan.2026.189557_bb0935","doi-asserted-by":"crossref","first-page":"67373","DOI":"10.18632\/oncotarget.12033","article-title":"Adenosine A3 receptor elicits chemoresistance mediated by multiple resistance-associated protein-1 in human glioblastoma stem-like cells","volume":"7","author":"Torres","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189557_bb0940","doi-asserted-by":"crossref","first-page":"11768","DOI":"10.1080\/21655979.2021.2009976","article-title":"RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1)","volume":"12","author":"Xu","year":"2021","journal-title":"Bioengineered"},{"key":"10.1016\/j.bbcan.2026.189557_bb0945","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41419-020-03113-5","article-title":"RPN2 is targeted by miR-181c and mediates glioma progression and temozolomide sensitivity via the wnt\/\u03b2-catenin signaling pathway","volume":"11","author":"Sun","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb0950","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12943-018-0812-2","article-title":"New insights into long noncoding RNAs and their roles in glioma","volume":"17","author":"Peng","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb0955","doi-asserted-by":"crossref","first-page":"10266","DOI":"10.18632\/aging.102455","article-title":"Silencing lncRNA FOXD2-AS1 inhibits proliferation, migration, invasion and drug resistance of drug-resistant glioma cells and promotes their apoptosis via microRNA-98-5p\/CPEB4 axis","volume":"11","author":"Gu","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.bbcan.2026.189557_bb0960","doi-asserted-by":"crossref","first-page":"12094","DOI":"10.1111\/jcmm.15846","article-title":"LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470\/miR-134\/Myc\/ABCC1 axis in glioma","volume":"24","author":"Wu","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0965","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20201111","article-title":"LncRNA NEAT1 promotes malignant phenotypes and TMZ resistance in glioblastoma stem cells by regulating let-7g-5p\/MAP3K1 axis","volume":"40","author":"Bi","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.bbcan.2026.189557_bb0970","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s10571-020-00898-z","article-title":"LncRNA MIR155HG promotes temozolomide resistance by activating the Wnt\/\u03b2-catenin pathway via binding to PTBP1 in glioma","volume":"41","author":"He","year":"2021","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.bbcan.2026.189557_bb0975","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2013.03.004","article-title":"Influence of metabolism on epigenetics and disease","volume":"153","author":"Kaelin","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189557_bb0980","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/neuonc\/noad232","article-title":"Metabolic modulation of histone acetylation mediated by HMGCL activates the FOXM1\/\u03b2-catenin pathway in glioblastoma","volume":"26","author":"Sun","year":"2024","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb0985","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1101\/gad.311027.117","article-title":"Acetyl-CoA promotes glioblastoma cell adhesion and migration through Ca2+\u2013NFAT signaling","volume":"32","author":"Lee","year":"2018","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2026.189557_bb0990","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s12276-020-0375-3","article-title":"Amino acids in cancer","volume":"52","author":"Lieu","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb0995","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90019","article-title":"Nicotinamide metabolism regulates glioblastoma stem cell maintenance","volume":"2","author":"Jung","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbcan.2026.189557_bb1000","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1158\/2159-8290.CD-23-1348","article-title":"Phosphocreatine promotes epigenetic reprogramming to facilitate glioblastoma growth through stabilizing BRD2","volume":"14","author":"Chen","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189557_bb1005","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1084\/jem.20101470","article-title":"Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme","volume":"208","author":"Wolf","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb1010","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.cmet.2024.07.011","article-title":"Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma","volume":"36","author":"Li","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbcan.2026.189557_bb1015","first-page":"ii3","article-title":"MOMC-2. Glioblastoma metabolic symbiosis: when lactate takes the lead","volume":"3","author":"Guyon","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.bbcan.2026.189557_bb1020","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202115343","article-title":"Lactate dehydrogenases promote glioblastoma growth and invasion via a metabolic symbiosis","volume":"14","author":"Guyon","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb1025","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00109-020-01965-0","article-title":"Revisiting lactate dynamics in cancer\u2014a metabolic expertise or an alternative attempt to survive?","volume":"98","author":"Mendes","year":"2020","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb1030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103134","article-title":"Targeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TAT-Cx43266\u2013283","volume":"62","author":"Pelaz","year":"2020","journal-title":"eBioMedicine"},{"key":"10.1016\/j.bbcan.2026.189557_bb1035","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2000446","article-title":"EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy","volume":"2","author":"Guo","year":"2009","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbcan.2026.189557_bb1040","article-title":"Tumor microenvironment in glioblastoma: current and emerging concepts","volume":"5","author":"Sharma","year":"2023","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.bbcan.2026.189557_bb1045","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/glia.23520","article-title":"Astrocytes, the rising stars of the glioblastoma microenvironment","volume":"67","author":"Brandao","year":"2019","journal-title":"Glia"},{"key":"10.1016\/j.bbcan.2026.189557_bb1050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.canlet.2018.06.041","article-title":"Delivery of MGMT mRNA to glioma cells by reactive astrocyte-derived exosomes confers a temozolomide resistance phenotype","volume":"433","author":"Yu","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189557_bb1055","first-page":"648","article-title":"GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity","volume":"4","author":"Watson","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2026.189557_bb1060","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/0008-5472.CAN-23-0609","article-title":"Neuronal activity promotes glioma progression by inducing proneural-to-mesenchymal transition in glioma stem cells","volume":"84","author":"Guo","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb1065","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cell.2015.04.012","article-title":"Neuronal activity promotes glioma growth through neuroligin-3 secretion","volume":"161","author":"Venkatesh","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189557_bb1070","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nature24014","article-title":"Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma","volume":"549","author":"Venkatesh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189557_bb1075","article-title":"New insights into monocyte-derived macrophages in glioblastoma","volume":"8","author":"Li","year":"2025","journal-title":"Research (Wash., D. C.)"},{"key":"10.1016\/j.bbcan.2026.189557_bb1080","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","article-title":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","volume":"573","author":"Venkataramani","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189557_bb1085","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41586-023-06036-1","article-title":"Glioblastoma remodelling of human neural circuits decreases survival","volume":"617","author":"Krishna","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189557_bb1090","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41467-021-21117-3","article-title":"Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma","volume":"12","author":"Jung","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb1095","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41588-021-00874-3","article-title":"Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer","volume":"53","author":"Kocakavuk","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2026.189557_bb1100","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/ng.3590","article-title":"Clonal evolution of glioblastoma under therapy","volume":"48","author":"Wang","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2026.189557_bb1105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","article-title":"Temozolomide resistance in glioblastoma multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Genes Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb1110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00099","article-title":"DAMP-mediated activation of NLRP3-inflammasome in brain sterile inflammation: the fine line between healing and neurodegeneration","volume":"5","author":"Rubartelli","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40824-023-00391-w","article-title":"Inhibition of DAMP actions in the tumoral microenvironment using lactoferrin-glycyrrhizin conjugate for glioblastoma therapy","volume":"27","author":"Kim","year":"2023","journal-title":"Biomater. Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb1120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1742-2094-8-32","article-title":"Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma","volume":"8","author":"Tafani","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bbcan.2026.189557_bb1125","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s12672-025-02567-3","article-title":"Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance","volume":"16","author":"Pu","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122708","article-title":"Targeted reprogramming of tumor-associated macrophages for overcoming glioblastoma resistance to chemotherapy and immunotherapy","volume":"311","author":"Li","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbcan.2026.189557_bb1135","article-title":"Tumor-associated macrophages nano-reprogrammers induce \u201cgear effect\u201d to empower glioblastoma immunotherapy","volume":"21","author":"Wang","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.bbcan.2026.189557_bb1140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189557_bb1145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/BCJ20200710","article-title":"Patient-derived glioblastoma stem cells transfer mitochondria through tunneling nanotubes in tumor organoids","volume":"478","author":"Pinto","year":"2021","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbcan.2026.189557_bb1150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051207","article-title":"Intercellular communication in the brain through tunneling nanotubes","volume":"14","author":"Khattar","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189557_bb1155","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1221671","article-title":"GFAP serves as a structural element of tunneling nanotubes between glioblastoma cells and could play a role in the intercellular transfer of mitochondria","volume":"11","author":"Simone","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1160","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1039\/D4NR03174A","article-title":"Nanoparticle shape is the game-changer for blood\u2013brain barrier crossing and delivery through tunneling nanotubes among glioblastoma cells","volume":"17","author":"Sierri","year":"2025","journal-title":"Nanoscale"},{"key":"10.1016\/j.bbcan.2026.189557_bb1165","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93775-8","article-title":"Tunneling nanotubes, TNT, communicate glioblastoma with surrounding non-tumor astrocytes to adapt them to hypoxic and metabolic tumor conditions","volume":"11","author":"Valdebenito","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189557_bb1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101450","article-title":"Tunneling nanotubes mediate adaptation of glioblastoma cells to temozolomide and ionizing radiation treatment","volume":"23","author":"Valdebenito","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.bbcan.2026.189557_bb1175","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1186\/s12885-025-15204-7","article-title":"Effect of chemotherapeutic drugs and cytochalasin B on tunneling nanotubes in U87 MG cells","volume":"25","author":"Matejka","year":"2025","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189557_bb1180","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/15548627.2022.2080382","article-title":"Protective effect of the tunneling nanotube-TNFAIP2\/M-sec system on podocyte autophagy in diabetic nephropathy","volume":"19","author":"Barutta","year":"2023","journal-title":"Autophagy"},{"key":"10.1016\/j.bbcan.2026.189557_bb1185","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/neuonc\/noac006","article-title":"New targets in the glioblastoma tumor microtube multiverse: emerging roles for the TGF-\u03b2\/TSP1 signaling axis","volume":"24","author":"Becker","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1190","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41467-024-45067-8","article-title":"A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1","volume":"15","author":"Hai","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb1195","article-title":"Glioblastoma tumor microtubes and brain fatty acid-binding protein: path to directional infiltration","author":"Choi","year":"2025","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1200","doi-asserted-by":"crossref","first-page":"6837","DOI":"10.1523\/JNEUROSCI.3532-16.2017","article-title":"Tweety-homolog 1 drives brain colonization of gliomas","volume":"37","author":"Jung","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbcan.2026.189557_bb1205","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1158\/2767-9764.CRC-23-0144","article-title":"Mitochondria transfer from mesenchymal stem cells confers chemoresistance to glioblastoma stem cells through metabolic rewiring","volume":"3","author":"Nakhle","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb1210","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107382","article-title":"Mitochondrial transfer as a strategy for enhancing cancer cell fitness:current insights and future directions","volume":"208","author":"Marabitti","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb1215","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/embj.201386030","article-title":"Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy","volume":"33","author":"Ahmad","year":"2014","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2026.189557_bb1220","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2016.00107","article-title":"Mitochondria know no boundaries: mechanisms and functions of intercellular mitochondrial transfer","volume":"4","author":"Torralba","year":"2016","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1225","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11060-025-05242-3","article-title":"Circadian variation in MGMT promoter methylation and expression predicts sensitivity to temozolomide in glioblastoma","volume":"176","author":"Gonzalez-Aponte","year":"2025","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1230","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12964-023-01398-5","article-title":"Interplay of oxidative stress, cellular communication and signaling pathways in cancer","volume":"22","author":"Iqbal","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bbcan.2026.189557_bb1235","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41419-025-07514-2","article-title":"Cytoplasmic connexin43-microtubule interactions promote glioblastoma stem-like cell maintenance and tumorigenicity","volume":"16","author":"Smyth","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb1240","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41389-022-00378-7","article-title":"Connexin 43 confers chemoresistance through activating PI3K","volume":"11","author":"Pridham","year":"2022","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bbcan.2026.189557_bb1245","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/pr.117.014944","article-title":"Current challenges and opportunities in treating glioblastoma","volume":"70","author":"Shergalis","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbcan.2026.189557_bb1250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2020.02.002","article-title":"Immunotherapy for glioma: current management and future application","volume":"476","author":"Xu","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189557_bb1255","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/neuros\/nyaa412","article-title":"A phase II and pharmacodynamic trial of RO4929097 for patients with recurrent\/progressive glioblastoma","volume":"88","author":"Peereboom","year":"2021","journal-title":"Neurosurgery"},{"key":"10.1016\/j.bbcan.2026.189557_bb1260","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s10637-020-00910-9","article-title":"Phase 1b\/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma","volume":"38","author":"Wick","year":"2020","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bbcan.2026.189557_bb1265","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/neuonc\/noy078","article-title":"A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098","volume":"20","author":"Brown","year":"2018","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1270","first-page":"283","article-title":"Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the alliance for clinical trials in oncology","volume":"6","author":"Cerhan","year":"2019","journal-title":"Neurooncol. Pract."},{"issue":"13","key":"10.1016\/j.bbcan.2026.189557_bb1275","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1158\/1078-0432.CCR-22-2807","article-title":"Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma","volume":"29","author":"Kelly","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb1280","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015749","article-title":"Targeted therapy with anlotinib for patient with recurrent glioblastoma: a case report and literature review","volume":"98","author":"Lv","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.bbcan.2026.189557_bb1285","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101141","article-title":"Phase I clinical trial of a novel procaspase-3 activator SM-1 with temozolomide in recurrent high-grade gliomas","volume":"61","author":"Huang","year":"2025","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189557_bb1290","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12943-023-01835-6","article-title":"Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial","volume":"22","author":"Bos","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb1295","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1089\/jmf.2023.K.0026","article-title":"Review of patents for anticancer agents targeting adenosine monophosphate-activated protein kinase","volume":"26","author":"Choi","year":"2023","journal-title":"J. Med. Food"},{"key":"10.1016\/j.bbcan.2026.189557_bb1300","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.18.01207","article-title":"Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial","volume":"37","author":"Wen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1305","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/neuonc\/noy161","article-title":"N2M2 (NOA-20) phase I\/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma","volume":"21","author":"Wick","year":"2019","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1310","first-page":"862","article-title":"Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma","volume":"17","author":"Lee","year":"2015","journal-title":"Neurooncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1315","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/tomography8020057","article-title":"Final report on clinical outcomes and tumor recurrence patterns of a pilot study assessing efficacy of belinostat (PXD-101) with chemoradiation for newly diagnosed glioblastoma","volume":"8","author":"Xu","year":"2022","journal-title":"Tomography"},{"key":"10.1016\/j.bbcan.2026.189557_bb1320","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1200\/JCO.19.03327","article-title":"Ivosidenib in isocitrate dehydrogenase 1\u2013mutated advanced glioma","volume":"38","author":"Mellinghoff","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189557_bb1325","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1158\/1078-0432.CCR-21-1096","article-title":"A phase 0 trial of ceritinib in patients with brain metastases and recurrent glioblastoma","volume":"28","author":"Mehta","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb1330","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70015","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: results from the phase 2 LEAP-005 study recurrent glioblastoma cohort","volume":"131","author":"Rha","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb1335","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00280-011-1721-x","article-title":"A phase I study of bortezomib and temozolomide in patients with advanced solid tumors","volume":"69","author":"Portnow","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1340","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11060-019-03258-0","article-title":"Tumor pharmacokinetics and pharmacodynamics of the CDK4\/6 inhibitor ribociclib in patients with recurrent glioblastoma","volume":"144","author":"Miller","year":"2019","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1345","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1200\/JCO.23.00493","article-title":"Inaugural results of the individualized screening trial of innovative glioblastoma therapy: a phase II platform trial for newly diagnosed glioblastoma using Bayesian adaptive randomization","volume":"41","author":"Rahman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1350","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","article-title":"Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential","volume":"6","author":"Gan","year":"2018","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb1355","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189557_bb1360","first-page":"1063","article-title":"Cancer cell plasticity during tumor progression, metastasis and response to therapy","volume":"4","author":"P\u00e9rez-Gonz\u00e1lez","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2026.189557_bb1365","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1158\/0008-5472.CAN-21-3629","article-title":"Chi3l1 is a modulator of glioma stem cell states and a therapeutic target in glioblastoma","volume":"83","author":"Guetta-Terrier","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb1370","doi-asserted-by":"crossref","first-page":"9570","DOI":"10.1021\/acs.nanolett.5c01141","article-title":"A metal\u2013phenolic network nanoresensitizer overcoming glioblastoma drug resistance through the metabolic adaptive strategy and targeting drug-tolerant cells","volume":"25","author":"Yin","year":"2025","journal-title":"Nano Lett."},{"key":"10.1016\/j.bbcan.2026.189557_bb1375","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.1038\/s41467-024-51214-y","article-title":"Multi-omics and pharmacological characterization of patient-derived glioma cell lines","volume":"15","author":"Wu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb1380","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104239","article-title":"Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM","volume":"83","author":"Xiong","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbcan.2026.189557_bb1385","article-title":"Sequential inhibition of PARP and BET as a rational therapeutic strategy for glioblastoma","volume":"11","author":"Peng","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bbcan.2026.189557_bb1390","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/s41419-019-1387-6","article-title":"Interleukin-8\/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma","volume":"10","author":"Hasan","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189557_bb1395","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","article-title":"Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry","volume":"155","author":"Maniotis","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1400","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(18)30990-5","article-title":"Primary brain tumours in adults","volume":"392","author":"Lapointe","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2026.189557_bb1405","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11060-018-2989-z","article-title":"Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?","volume":"140","author":"Palmer","year":"2018","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1410","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11060-017-2383-2","article-title":"Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution","volume":"132","author":"Azoulay","year":"2017","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1415","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41591-025-03512-1","article-title":"Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma","volume":"31","author":"Long","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb1420","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41416-025-02977-8","article-title":"CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma","volume":"132","author":"Strassheimer","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb1425","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1430","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1021\/acschembio.5c00039","article-title":"Optimizing peptide-conjugated lipid nanoparticles for efficient siRNA delivery across the blood-brain barrier and treatment of glioblastoma multiforme","volume":"20","author":"Tong","year":"2025","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1435","article-title":"Targeting brain drug delivery with macromolecules through receptor-mediated transcytosis","volume":"17","author":"Li","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbcan.2026.189557_bb1440","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s13205-025-04639-1","article-title":"Mesoporous silica nanoparticles in glioblastoma: smart nano-platforms for targeted therapy and precision diagnosis","volume":"16","author":"Hiremath","year":"2026","journal-title":"3 Biotech"},{"key":"10.1016\/j.bbcan.2026.189557_bb1445","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1021\/acsbiomaterials.3c00263","article-title":"Angiopep-2 grafted PAMAM dendrimers for the targeted delivery of temozolomide: in vitro and in vivo effects of PEGylation in the management of glioblastoma multiforme","volume":"9","author":"Sahoo","year":"2023","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.bbcan.2026.189557_bb1450","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/s41467-018-04315-4","article-title":"Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles","volume":"9","author":"Lam","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb1455","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16193300","article-title":"Blood\u2013brain barrier conquest in glioblastoma nanomedicine: strategies, clinical advances, and emerging challenges","volume":"16","author":"Duan","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189557_bb1460","doi-asserted-by":"crossref","first-page":"41819","DOI":"10.1021\/acsami.4c05691","article-title":"Targeted delivery of nanoparticle-conveyed neutrophils to the glioblastoma site for efficient therapy","volume":"16","author":"Piao","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bbcan.2026.189557_bb1465","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/acs.nanolett.1c00818","article-title":"Tumor-associated-macrophage-membrane-coated nanoparticles for improved photodynamic immunotherapy","volume":"21","author":"Chen","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.bbcan.2026.189557_bb1470","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12645-023-00167-w","article-title":"Functional targeted therapy for glioma based on platelet membrane-coated nanogels","volume":"14","author":"Li","year":"2023","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1475","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12951-021-01002-3","article-title":"Combination of cell-penetrating peptides with nanomaterials for the potential therapeutics of central nervous system disorders: a review","volume":"19","author":"Zhang","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1480","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/08982104.2023.2191718","article-title":"Development of tLyP-1 functionalized nanoliposomes with tunable internal water phase for glioma targeting","volume":"33","author":"Wang","year":"2023","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb1485","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1248\/bpb.b23-00630","article-title":"NRP1 induces enhanced stemness and chemoresistance in glioma cells via YAP","volume":"47","author":"Jin","year":"2024","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bbcan.2026.189557_bb1490","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","article-title":"Cancer neuroscience: state of the field, emerging directions","volume":"186","author":"Winkler","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189557_bb1495","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3390\/cells10051226","article-title":"Glutamatergic mechanisms in glioblastoma and tumor-associated epilepsy","volume":"10","author":"Lange","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189557_bb1500","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/brainsci13020326","article-title":"Perampanel in brain tumor-related epilepsy: a systematic review","volume":"13","author":"Tabaee Damavandi","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.bbcan.2026.189557_bb1505","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12885-024-11846-1","article-title":"PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma","volume":"24","author":"Heuer","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb1510","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines14010072","article-title":"Neuron\u2013glioma synapses in tumor progression","volume":"14","author":"Cueto-Ure\u00f1a","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbcan.2026.189557_bb1515","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11060-022-04154-w","article-title":"NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells","volume":"160","author":"Tsuji","year":"2022","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-024-04719-x","article-title":"Central nervous system regulation of diffuse glioma growth and invasion: from single unit physiology to circuit remodeling","volume":"169","author":"Picart","year":"2024","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1525","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.593578","article-title":"NTRK fusions and TRK inhibitors: potential targeted therapies for adult glioblastoma","volume":"10","author":"Wang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1530","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf201.1770","article-title":"TMIC-15. Reactive oligodendrocytes promote glioblastoma progression via CCL5\/CCR5-mediated glioma stem cell maintenance","volume":"27","author":"Mikolajewicz","year":"2025","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1535","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.neuron.2025.12.012","article-title":"Reactive oligodendrocytes promote glioblastoma progression through CCL5\/CCR5-mediated glioma stem cell maintenance","volume":"114","author":"Mikolajewicz","year":"2026","journal-title":"Neuron"},{"key":"10.1016\/j.bbcan.2026.189557_bb1540","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/neuonc\/noab092","article-title":"Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma","volume":"23","author":"Schneider","year":"2021","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1545","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/ph14030195","article-title":"Inhibition of intercellular cytosolic traffic via gap junctions reinforces lomustine-induced toxicity in glioblastoma independent of MGMT promoter methylation status","volume":"14","author":"Schneider","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbcan.2026.189557_bb1550","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13063-021-05977-0","article-title":"Phase I\/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth\/NOA-24 trial","volume":"23","author":"Zeyen","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.bbcan.2026.189557_bb1555","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1878-0261.13786","article-title":"Tonabersat enhances temozolomide-mediated cytotoxicity in glioblastoma by disrupting intercellular connectivity through connexin 43 inhibition","volume":"19","author":"Schmidt","year":"2025","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1560","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/0008-5472.CAN-15-1286","article-title":"Connexin 43 inhibition sensitizes chemoresistant glioblastoma cells to temozolomide","volume":"76","author":"Murphy","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb1565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/or.2021.7995","article-title":"Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide","volume":"45","author":"Yang","year":"2021","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2026.189557_bb1570","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1158\/1078-0432.CCR-25-0018","article-title":"Innovative therapeutic strategies targeting the network architecture of glioblastoma","volume":"31","author":"Beichert","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189557_bb1575","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1158\/2159-8290.CD-24-0414","article-title":"Screening for tumor microtube-targeting drugs identifies PKC modulators as multipotent inhibitors of glioblastoma progression","volume":"16","author":"Azor\u00edn","year":"2026","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189557_bb1580","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.3390\/ijms26157652","article-title":"Microtubule-targeting agents: advances in tubulin binding and small molecule therapy for gliomas and neurodegenerative diseases","volume":"26","author":"Ezzo","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189557_bb1585","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11060-024-04786-0","article-title":"Disrupting glioblastoma networks with tumor treating fields (TTFields) in in vitro models","volume":"170","author":"Schlieper-Scherf","year":"2024","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1590","article-title":"A brain-penetrant microtubule-targeting agent that disrupts hallmarks of glioma tumorigenesis","volume":"3","author":"Horne","year":"2021","journal-title":"Neuro Oncol. Adv."},{"key":"10.1016\/j.bbcan.2026.189557_bb1595","doi-asserted-by":"crossref","first-page":"vii80","DOI":"10.1093\/neuonc\/noac209.305","article-title":"CTNI-40. Phase I trial of sulfasalazine combined with stereotactic radiosurgery for recurrent glioblastoma: study protocol for NCT04205357","volume":"24","author":"Skeie","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1600","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/dmd.112.048322","article-title":"Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma","volume":"41","author":"Agarwal","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbcan.2026.189557_bb1605","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11060-024-04795-z","article-title":"Focused ultrasound-mediated enhancement of blood\u2013brain barrier permeability for brain tumor treatment: a systematic review of clinical trials","volume":"170","author":"Zhu","year":"2024","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1610","doi-asserted-by":"crossref","first-page":"iii32","DOI":"10.1093\/neuonc\/nou208.37","article-title":"High interstitial fluid pressure regulates tumor growth and drug uptake in human glioblastoma","volume":"16","author":"Persson","year":"2014","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1615","article-title":"Quisinostat is a brain-penetrant radiosensitizer in glioblastoma","volume":"8","author":"Lo Cascio","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbcan.2026.189557_bb1620","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/ijms25042316","article-title":"Epidermal growth factor receptor inhibitors in glioblastoma: current status and future possibilities","volume":"25","author":"Ezzati","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189557_bb1625","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1158\/1078-0432.CCR-16-1276","article-title":"PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models","volume":"23","author":"Lin","year":"2017","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb1630","doi-asserted-by":"crossref","first-page":"1724278","DOI":"10.3389\/fonc.2025.1724278","article-title":"Context-specific targeting of focal adhesion kinase in brain tumors: lessons from glioblastoma and neurofibromatosis type 2-mutant meningioma","volume":"15","author":"Sagerer","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1635","doi-asserted-by":"crossref","DOI":"10.3390\/cells13120998","article-title":"Overcoming barriers in glioblastoma\u2014advances in drug delivery strategies","volume":"13","author":"ter Linden","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189557_bb1640","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/neuonc\/nox161","article-title":"Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of alliance N0874\/ABTC 02","volume":"20","author":"Galanis","year":"2018","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1645","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12943-017-0670-3","article-title":"Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189557_bb1650","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/neuonc\/noae053","article-title":"Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial","volume":"26","author":"Roth","year":"2024","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1655","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1097\/MS9.0000000000003869","article-title":"Safety and efficacy of Depatuxizumab mafodotin monotherapy or in combination with temozolomide in patients with\/without EGFR-amplified recurrent glioblastoma: a systematic review","volume":"87","author":"Moghib","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.bbcan.2026.189557_bb1660","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/neuonc\/nor198","article-title":"Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study","volume":"14","author":"Friday","year":"2012","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1665","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910570","article-title":"Review of novel surgical, radiation, and systemic therapies and clinical trials in glioblastoma","volume":"25","author":"Valerius","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189557_bb1670","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v11i6.3994","article-title":"The glioblastoma landscape: hallmarks of disease, therapeutic resistance, and treatment opportunities","volume":"11","author":"Boylan","year":"2023","journal-title":"Med. Res. Arch."},{"key":"10.1016\/j.bbcan.2026.189557_bb1675","first-page":"1","article-title":"The regulatory role of CDK4\/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (review)","volume":"56","author":"He","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189557_bb1680","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/neuonc\/now009","article-title":"A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma","volume":"18","author":"Brandes","year":"2016","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1685","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071\u201322072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1690","first-page":"1534","article-title":"A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets","volume":"3","author":"Wang","year":"2022","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2026.189557_bb1695","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3390\/biom15050658","article-title":"Liquid biopsy-derived tumor biomarkers for clinical applications in glioblastoma","volume":"15","author":"de Lima","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbcan.2026.189557_bb1700","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/neuonc\/nox119","article-title":"Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha","volume":"20","author":"Olmez","year":"2018","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1705","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1158\/1078-0432.CCR-24-0562","article-title":"CDKN2A\/B homozygous deletion sensitizes IDH-mutant glioma to CDK4\/6 inhibition","volume":"30","author":"Nasser","year":"2024","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189557_bb1710","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","article-title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study","volume":"27","author":"Galanis","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1715","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11060-019-03227-7","article-title":"Phase I\/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed\/refractory glioblastoma (phase II)","volume":"144","author":"Hainsworth","year":"2019","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1720","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1725","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/neuonc\/noac173","article-title":"Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial","volume":"25","author":"Lassman","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1730","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11060-022-04193-3","article-title":"ABTC-0904: targeting glioma stem cells in GBM: a phase 0\/II study of hedgehog pathway inhibitor GDC-0449","volume":"161","author":"Sloan","year":"2023","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1735","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.2047","article-title":"Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: final phase 2 study results","author":"Wen","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189557_bb1740","article-title":"Multiple patient-derived glioblastoma models reveal synthetic lethality through concurrent PI3K and CDK4\/6 inhibition by blocking trans-active cooperation","author":"Zhang","year":"2025","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1745","doi-asserted-by":"crossref","first-page":"ii73","DOI":"10.1093\/neuonc\/noac174.254","article-title":"P11.65.B GBM AGILE: a global, phase 2\/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma","volume":"24","author":"Weller","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bbcan.2026.189557_bb1750","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65888-5","article-title":"Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma","volume":"16","author":"Joun","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189557_bb1755","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114139","article-title":"Multiplexed single-cell lineage tracing of mitotic kinesin inhibitor resistance in glioblastoma","volume":"43","author":"Cheng","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2026.189557_bb1760","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl0515","article-title":"Single-cell nanobiopsy enables multigenerational longitudinal transcriptomics of cancer cells","volume":"10","author":"Marcuccio","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2026.189557_bb1765","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3390\/cells14191540","article-title":"Integrated spatial and single-cell transcriptomics reveals poor prognostic ligand-receptor pairs in glioblastoma","volume":"14","author":"Yoshimoto","year":"2025","journal-title":"Cells"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:32:55Z","timestamp":1782030775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26000296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":353,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0304419X26000296"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189557","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glioblastoma cell plasticity: A new paradigm in glioblastoma therapeutic resistance","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189557"}}